POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
Potassium chloride provides potassium ions for maintenance of normal electrolyte balance; potassium is the principal intracellular cation. Dextrose provides caloric supplementation. Lactated Ringer's solution provides electrolytes (sodium, chloride, potassium, calcium, lactate) to maintain fluid and electrolyte balance, with lactate serving as a bicarbonate precursor.
| Metabolism | Potassium: primarily cellular uptake via Na+/K+-ATPase, excreted renally. Dextrose is rapidly metabolized via glycolysis to carbon dioxide and water, yielding energy; excess may be stored as glycogen or fat. Lactate is converted to bicarbonate in the liver via gluconeogenesis. |
| Excretion | Renal excretion of potassium: >90% eliminated by kidneys, with obligatory secretion in distal tubules and collecting ducts. Fecal excretion: <10% via colonic secretion. Minimal biliary elimination. |
| Half-life | Potassium has no true elimination half-life as it is not metabolized; distribution half-life is approximately 2 hours for intravenous potassium. Clinically, redistribution from extracellular to intracellular space (driven by insulin, beta-adrenergic tone, and acid-base status) determines serum concentration changes. |
| Protein binding | <2% bound to plasma proteins; potassium is primarily free and ionized in serum. |
| Volume of Distribution | 0.5-0.7 L/kg (total body water), reflecting distribution primarily in extracellular fluid and rapid equilibration with intracellular compartment. Clinical meaning: Large Vd indicates extensive tissue uptake; loading doses may be required for repletion. |
| Bioavailability | Intravenous: 100% (administered directly into bloodstream). Oral: ~90% absorbed; first-pass effect negligible. Not administered via other routes. |
| Onset of Action | Intravenous: Onset of effect on serum potassium levels within minutes; correction of hypokalemia typically observed within 1-2 hours. Redistribution to intracellular space occurs rapidly. |
| Duration of Action | Intravenous: Duration of effect on serum potassium depends on dose and continuous infusion; for a single dose, effect may last 2-4 hours due to rapid redistribution and renal excretion. Continuous infusion is needed to maintain serum levels. |
| Molecular Weight | 74.55 |
Intravenous administration of 5 mEq potassium chloride in 5% dextrose and lactated Ringer's solution per 100 mL bag, administered at a rate not exceeding 10 mEq/hour (0.3 mEq/kg/hour) for adults, with typical daily dose of 40-100 mEq depending on serum potassium levels and clinical status; continuous infusion or intermittent dosing as per protocol.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 30-50 mL/min: reduce dose by 25-50% and monitor potassium. GFR 10-29 mL/min: administer with extreme caution; initial dose 50% of usual and titrate based on serum K+. GFR < 10 mL/min: avoid unless severe hypokalemia with dialysis; use with close monitoring. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce initial dose by 25% and monitor potassium. Child-Pugh C: use with caution; reduce dose by 50% and frequent monitoring due to increased risk of hyperkalemia from altered electrolyte handling. |
| Pediatric use | Intravenous: 0.5-1 mEq/kg/dose (maximum 30 mEq/dose) administered at a rate not exceeding 0.3 mEq/kg/hour; daily requirement 2-3 mEq/kg/day. Specific concentration in dextrose 5% and lactated Ringer's solution should be verified for pediatric use; typically not recommended as standard solution due to dextrose content. |
| Geriatric use | Elderly patients: start at low end of dosing (20-40 mEq/day) with maximum rate of 5 mEq/hour; monitor renal function and serum potassium frequently due to age-related decline in GFR and increased sensitivity to potassium loads. |
| 1st trimester | Potassium chloride is normal plasma constituent; use only if clearly needed. No known teratogenic risk. |
| 2nd trimester | Same as t1; monitor serum potassium levels to avoid hyperkalemia. |
| 3rd trimester | Use with caution; close monitoring of potassium levels and fetal heart rate if given intravenously. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta by active transport; fetal levels are regulated. No specific data on exogenous KCl transfer. |
| Breastfeeding | Potassium chloride is a normal component of breast milk; supplementation does not significantly alter milk levels. Use with caution only if maternal serum potassium is low. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is not teratogenic. Dextrose and lactated Ringer's are generally safe. No increased risk of fetal malformations across trimesters. High doses or rapid infusion may cause maternal electrolyte disturbances affecting fetal well-being. |
| Fetal Monitoring | Monitor serum electrolytes, renal function, acid-base status, and ECG in mother. Assess fetal heart rate if infusion is rapid or high volume. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride, dextrose, or lactated Ringer's. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use. Do not administer undiluted or rapid infusion; can cause cardiac arrest or fatal hyperkalemia.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguriaAdrenal insufficiencyAcute dehydrationConcurrent use of potassium-sparing diureticsSevere hemolytic reactions
| Precautions | Risk of hyperkalemia, especially in renal impairment or patients on ACE inhibitors/ARBs/potassium-sparing diuretics, Monitor serum potassium and ECG during infusion, Avoid extravasation due to risk of tissue necrosis, Use caution in patients with heart failure, pulmonary edema, or renal impairment, Dextrose solutions may cause hyperglycemia in diabetic patients |
| Food/Dietary | Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, potatoes, spinach, avocados) and potassium-containing salt substitutes while receiving this IV solution, as it may increase risk of hyperkalemia. |
| Clinical Pearls | This combination is used for maintenance fluid and electrolyte replacement. Potassium concentration (5 mEq/100 mL) is suitable for peripheral vein administration but can cause phlebitis; monitor infusion site. Do not use in patients with hyperkalemia, renal failure, or severe metabolic acidosis. Lactated Ringer's provides bicarbonate precursors; avoid in lactic acidosis. Use with caution in patients receiving potassium-sparing diuretics or ACE inhibitors. Maximum infusion rate: 10 mEq/hour potassium. Check serum potassium before administration in renal impairment. |
| Patient Advice | This medication is given intravenously to replace fluids and potassium. · Report any pain, redness, or swelling at the IV site immediately. · Do not consume potassium-rich foods or salt substitutes without consulting your doctor. · Inform your doctor if you have kidney problems, heart disease, or are taking diuretics or blood pressure medications. · You may experience a metallic taste or burning sensation at the IV site; these are usually temporary. |
Loading safety data…